88 related articles for article (PubMed ID: 7654018)
41. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
Spruce BA; Campbell LA; McTavish N; Cooper MA; Appleyard MV; O'Neill M; Howie J; Samson J; Watt S; Murray K; McLean D; Leslie NR; Safrany ST; Ferguson MJ; Peters JA; Prescott AR; Box G; Hayes A; Nutley B; Raynaud F; Downes CP; Lambert JJ; Thompson AM; Eccles S
Cancer Res; 2004 Jul; 64(14):4875-86. PubMed ID: 15256458
[TBL] [Abstract][Full Text] [Related]
42. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model.
Triest JA; Grignon DJ; Cher ML; Kocheril SV; Montecillo EJ; Talati B; Tekyi-Mensah S; Pontes JE; Hillman GG
Clin Cancer Res; 1998 Aug; 4(8):2009-14. PubMed ID: 9717832
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
45. Cyclocreatine in cancer chemotherapy.
Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
[TBL] [Abstract][Full Text] [Related]
46. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis.
Kornacker M; Schlattner U; Wallimann T; Verneris MR; Negrin RS; Kornacker B; Staratschek-Jox A; Diehl V; Wolf J
Int J Cancer; 2001 Nov; 94(4):513-9. PubMed ID: 11745437
[TBL] [Abstract][Full Text] [Related]
47. Differential effects of creatine kinase isoenzymes and substrates on regeneration in livers of transgenic mice.
Askenasy N; Koretsky AP
Am J Physiol; 1997 Aug; 273(2 Pt 1):C741-6. PubMed ID: 9277372
[TBL] [Abstract][Full Text] [Related]
48. In vivo (1)H MRS and (31)P MRSI of the response to cyclocreatine in transgenic mouse liver expressing creatine kinase.
Cui MH; Jayalakshmi K; Liu L; Guha C; Branch CA
NMR Biomed; 2015 Dec; 28(12):1634-44. PubMed ID: 26451872
[TBL] [Abstract][Full Text] [Related]
49. Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine.
Martin KJ; Vassallo CD; Teicher BA; Kaddurah-Daouk R
Anticancer Drugs; 1995 Jun; 6(3):419-26. PubMed ID: 7670140
[TBL] [Abstract][Full Text] [Related]
50. Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.
Patel R; Ford CA; Rodgers L; Rushworth LK; Fleming J; Mui E; Zhang T; Watson D; Lynch V; Mackay G; Sumpton D; Sansom OJ; Vande Voorde J; Leung HY
Cancer Res; 2022 Jul; 82(14):2565-2575. PubMed ID: 35675421
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
Ara G; Gravelin LM; Kaddurah-Daouk R; Teicher BA
In Vivo; 1998; 12(2):223-31. PubMed ID: 9627806
[TBL] [Abstract][Full Text] [Related]
52. Cyclocreatine transport and cytotoxicity in rat glioma and human ovarian carcinoma cells: 31P-NMR spectroscopy.
Schiffenbauer YS; Meir G; Cohn M; Neeman M
Am J Physiol; 1996 Jan; 270(1 Pt 1):C160-9. PubMed ID: 8772441
[TBL] [Abstract][Full Text] [Related]
53. Soy extract reduces prostate cancer growth in mice, cell culture.
Urol Nurs; 2001 Dec; 21(6):411-2. PubMed ID: 11998508
[No Abstract] [Full Text] [Related]
54. Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity.
Maril N; Degani H; Rushkin E; Sherry AD; Cohn M
Am J Physiol; 1999 Oct; 277(4):C708-16. PubMed ID: 10516101
[TBL] [Abstract][Full Text] [Related]
55. [Determination of CK-BB (E.C.2.7.3.2) in advanced stages of carcinoma of the prostate].
Jansen S; Mayor J; Arenas J; Fraile B; Santos I; Díaz-González R; Leiva O; Borobia V; Martínez A
Actas Urol Esp; 1986; 10(1):25-8. PubMed ID: 2425557
[No Abstract] [Full Text] [Related]
56. Cytotoxic agents in prostate cancer: an enigma.
Yagoda A
Semin Urol; 1983 Nov; 1(4):311-21. PubMed ID: 6399617
[No Abstract] [Full Text] [Related]
57. Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate.
LoPresti P; Cohn M
Biochim Biophys Acta; 1989 Oct; 998(3):317-20. PubMed ID: 2804134
[TBL] [Abstract][Full Text] [Related]
58. Submembranous recruitment of creatine kinase B supports formation of dynamic actin-based protrusions of macrophages and relies on its C-terminal flexible loop.
Venter G; Polling S; Pluk H; Venselaar H; Wijers M; Willemse M; Fransen JA; Wieringa B
Eur J Cell Biol; 2015 Feb; 94(2):114-27. PubMed ID: 25538032
[TBL] [Abstract][Full Text] [Related]
59. Electrophysiology and biochemical analysis of cyclocreatine uptake and effect in hippocampal slices.
Enrico A; Patrizia G; Luisa P; Alessandro P; Gianluigi L; Carlo G; Maurizio B
J Integr Neurosci; 2013 Jun; 12(2):285-97. PubMed ID: 23869866
[TBL] [Abstract][Full Text] [Related]
60. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.
Kurosawa Y; Degrauw TJ; Lindquist DM; Blanco VM; Pyne-Geithman GJ; Daikoku T; Chambers JB; Benoit SC; Clark JF
J Clin Invest; 2012 Aug; 122(8):2837-46. PubMed ID: 22751104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
